Go back to trials list
Ureteroscopic Laser Modality on Total Lasing Time and Total Energy in Patients With Large, Dense Renal Calculi
Description
This study will examine the effects of ureteroscopic lasing technique (dusting, fragmentation and a hybrid approach) on total lasing time and total energy in patients with a large renal calculi burden of single or multiple stones with the sum of its longest diameters between 10-20 mm and having mean Hounsfield units of 1000 or more.This study will examine the effects of ureteroscopic lasing technique (dusting, fragmentation and a hybrid approach) on total lasing time and total energy in patients with a large renal calculi burden of single or multiple stones with the sum of its longest diameters between 10-20 mm and having mean Hounsfield units of 1000 or more. Additionally, we will observe the impact of these parameters on total operative time.
Trial Eligibility
Inclusion Criteria: * Adults between the ages of 18-80. * Any gender, race or ethnicity may be included- these factors play a small, if any role on renal calculi formation and ability to withstand procedure. * Must be suitable for a flexible ureteroscopy as determined by the MD * Large renal calculi burden of single or multiple stones with the sum of its longest diameters between 10-20 mm * An average stone density of at least 1000 Hounsfield units. Exclusion Criteria: * Those with a stone burden less than 10mm or more than 20mm. * Those with an average stone density below 1000 Hounsfield units. * Patients who are dependent on mandatory anticoagulation therapies and cannot stop for surgery * Patients that cannot undergo ureteral access sheath placement * Patients with abnormal anatomy such as horseshoe kidney * Patients with a history of: * Ipsilateral upper urinary tract reconstructive procedures on the side of the renal calculi * Ipsilateral ureteral strictures * Prior radiotherapy of the abdomen or pelvis * Neurogenic bladder * Spinal cord injuries * Those who are pregnant * Currently being treated for infection or cancer
Study Info
Organization
Albany Medical College
Primary Outcome
Reduced OR time
Interventions
Locations Recruiting
Albany Medical College
United States, New York, Albany
Interested in joining this trial?
Our dedicated patient navigators are here to guide you through the validation and enrollment process with ease.
Get the latest thought leadership on your Kidney Disease delivered straight to your inbox
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.